Biodexa announces additional positive results of phase 2 trial of erapa in treatment of precancerous polyps in the gi tract - now 12-month data

Cardiff, uk / accesswire / july 11, 2024 / biodexa pharmaceuticals plc (nasdaq:bdrx), an acquisition-focused clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is making good progress with erapa™, its drug to treat familial adenomatous polyposis (fap). fap is a mostly inherited condition that puts people at a much greater risk of developing colorectal cancer.
BDRX Ratings Summary
BDRX Quant Ranking